Top-Performer: White Light Versus 5-ALA Fluorescence Guided Resection

0 views

|

June 15, 2021

Oncotarget published this research paper on August 11, 2020, entitled, “Survival after resection of brain metastases with white light microscopy versus fluorescence-guidance: A matched cohort analysis of the Metastasys study data,” by researchers from the University of Medicine Goettingen, Goettingen, Germany; University Medical Center Leipzig, Leipzig, Germany; University Hospital Muenster, Muenster, Germany. The cover for issue 32 of Oncotarget features Figure 2, "This figure depicts overall survival and local in-brain recurrence-free survival in the study's subgroups," by Hussein, et al. which reported that the aim of the present study is to assess whether the use of 5-ALA has an impact on local recurrence or survival compared to conventional white light microscopic tumor resection. Two groups were compared: In the “white light” group, resection was performed with conventional microscopy. In the 5-ALA group, fluorescence guided peritumoral resection was additionally performed after standard microscopic resection. Local in-brain recurrence occurred in 21/175 patients with a rate of 15/119 in the white light and 6/56 in the 5-ALA group. The use of 5-ALA did not result in lower in-brain recurrence or mortality compared to the use of white light microscopy. Dr. Bawarjan Schatlo from the Department of Neurosurgery at The University of Medicine Goettingen said, "Metastatic brain disease is more common than primary brain tumors." Another group made the case for extending tumor resection 5 millimeters into peritumoral tissue to perform a so-called supramarginal resection. Its aim is to prolong progression-free survival through radical resection and improved local tumor control. In a series of 52 patients, Kamp and colleagues detected positive fluorescence in 62% of resected cerebral metastases. Thus, the utility and importance of using methods to improve local control of brain metastases remains an unresolved issue. The aim of the current study was to compare survival and local recurrence in a cohort of patients who underwent surgery for brain metastases with 5-ALA fluorescence microscopy to one that was operated using microscopic white light only. The Schatlo Research Team concluded in their Oncotarget research paper, "the present study confirmed that regardless of surgical adjunct, radiotherapy is strongly associated with improved survival." To date, this research paper has generated an Altmetric Attention Score of 48. The Altmetric Attention Score provides an at-a-glance indication of the volume and type of online attention the research has received. Top Oncotarget publications rated by Altmetric Attention Score - https://www.oncotarget.com/news/altmetric/ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27688 DOI - https://doi.org/10.18632/oncotarget.27688 Full text - https://www.oncotarget.com/article/27688/text/ Correspondence to - Bawarjan Schatlo - bawarjan.schatlo@med.uni-goettingen.de Keywords - brain tumor, brain metastasis, fluorescence-guided surgery, 5-ALA About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget YouTube - https://www.youtube.com/c/OncotargetYouTube/ LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Cancer ResearchImaging/MicroscopyNeuroscience

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.